BioRefine Denmark A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 4.4% 9.4% 13.4%  
Credit score (0-100)  0 0 46 25 16  
Credit rating  N/A N/A BBB BB BB  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -4,316 -29,877 -65,488  
EBITDA  0.0 0.0 -8,457 -31,718 -66,812  
EBIT  0.0 0.0 -8,457 -31,718 -66,812  
Pre-tax profit (PTP)  0.0 0.0 -9,629.0 -34,437.0 -72,027.0  
Net earnings  0.0 0.0 -7,512.0 -34,437.0 -74,144.0  
Pre-tax profit without non-rec. items  0.0 0.0 -9,629 -34,437 -72,027  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 57,990 81,030 35,706  
Shareholders equity total  0.0 0.0 -1,512 -25,945 -30,573  
Interest-bearing liabilities  0.0 0.0 75,343 87,858 43,848  
Balance sheet total (assets)  0.0 0.0 88,263 88,484 48,104  

Net Debt  0.0 0.0 75,338 87,855 40,633  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -4,316 -29,877 -65,488  
Gross profit growth  0.0% 0.0% 0.0% -592.2% -119.2%  
Employees  0 0 12 13 12  
Employee growth %  0.0% 0.0% 0.0% 8.3% -7.7%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 88,263 88,484 48,104  
Balance sheet change%  0.0% 0.0% 0.0% 0.3% -45.6%  
Added value  0.0 0.0 -8,457.0 -31,718.0 -66,812.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 57,990 23,040 -40,803  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 195.9% 106.2% 102.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -9.4% -31.0% -69.2%  
ROI %  0.0% 0.0% -11.1% -35.7% -80.7%  
ROE %  0.0% 0.0% -8.5% -39.0% -108.6%  

Solidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% -1.7% -22.7% -38.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -890.8% -277.0% -60.8%  
Gearing %  0.0% 0.0% -4,983.0% -338.6% -143.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 3.1% 3.4% 7.9%  

Liquidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.3 0.1 0.3  
Current Ratio  0.0 0.0 0.4 0.1 0.3  
Cash and cash equivalent  0.0 0.0 5.0 3.0 3,215.0  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 -49,848.0 -57,735.0 -17,933.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 -705 -2,440 -5,568  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -705 -2,440 -5,568  
EBIT / employee  0 0 -705 -2,440 -5,568  
Net earnings / employee  0 0 -626 -2,649 -6,179